Literature DB >> 21762277

Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma.

J-X Huang1, W-C Chen, M Lin, Y-L Zhang, F-Y Li, Z-X Song, W Xiao, P Chen, R-Y Qian, E Salminen, H Yu.   

Abstract

The aim of this study was to examine the expression of the molecular markers cyclooxygenase-2 (COX-2), Ki-67, cyclin A, and p27 in patients with esophageal squamous cell carcinoma (ESCC), to ascertain the relationship of these makers with the clinicopathological significance of the patients, and to assess the additional prognostic value of the expression profile of these proteins for ESCC patients. The expression levels of COX-2, Ki-67, cyclin A, and p27 proteins of a series of primarily resected ESCC samples were determined by immunohistochemistry method. Clinicopathological and molecular factors affecting survival were analyzed by multivariate analysis. A total of 78 specimens were included in this study. Expression of COX-2 was observed in 43 (55.1%) cases, and high levels of expression of Ki-67, p27, and cyclin A were observed in 57 (73.0%), 33 (42.3%), 43 (55.1%) cases, respectively. The results of univariate survival analysis indicated that more advanced tumor stage, lymph node involvement, systemic dissemination, the levels of expression of COX-2, Ki-67, cyclin A, and p27 were associated with survival (all P-value < 0.05). Multifactorial survival analysis revealed that only lymph node involvement, over-expression of cyclin A, and low p27 expression were associated with the survival of the patients (hazard ratios = 2.83, 4.7, 2.9, respectively; P= 0.025, 0.042, 0.005, respectively). Among the molecular markers assessed, the expression of cell proliferation markers cyclin A and p27 are independent prognostic factors in patients with ESCC, whereas neither COX-2 nor Ki-67 is of independent prognostic value.
© 2011 Copyright the Authors. Journal compilation © 2011, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762277     DOI: 10.1111/j.1442-2050.2011.01219.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  8 in total

1.  Evaluation of tumor metastasis-associated markers for molecular classification in patients with esophageal squamous cell carcinoma.

Authors:  Jun-Xing Huang; Juan Yao; Mao-Song Lin; Mei Lin; Wei Xiao; Hong Yu; Ping Chen; Rong-Yu Qian
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma.

Authors:  Jun-Xing Huang; Shuang-LE Shen; Mei Lin; Wei Xiao; Wei-Chang Chen; Mao-Song Lin; Hong Yu; Ping Chen; Rong-Yu Qian
Journal:  Oncol Lett       Date:  2012-07-20       Impact factor: 2.967

3.  Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer.

Authors:  Jun Chen; Fang Wu; Hong-Lei Pei; Wen-Dong Gu; Zhong-Hua Ning; Ying-Jie Shao; Jin Huang
Journal:  Oncol Lett       Date:  2015-08-19       Impact factor: 2.967

Review 4.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

Review 5.  The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis.

Authors:  Zaoxiu Hu; Yanlong Yang; Yonghe Zhao; Yunchao Huang
Journal:  Onco Targets Ther       Date:  2017-06-09       Impact factor: 4.147

6.  Krt5+/Krt15+ foregut basal progenitors give rise to cyclooxygenase-2-dependent tumours in response to gastric acid stress.

Authors:  Hyeongsun Moon; Jerry Zhu; Leanne R Donahue; Eunju Choi; Andrew C White
Journal:  Nat Commun       Date:  2019-05-20       Impact factor: 14.919

7.  MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.

Authors:  Ying Shao; Peng Li; Sheng-Tao Zhu; Ji-Ping Yue; Xiao-Jun Ji; Dan Ma; Li Wang; Yong-Jun Wang; Ye Zong; Yong-Dong Wu; Shu-Tian Zhang
Journal:  Oncotarget       Date:  2016-03-22

8.  Clinical significances of p27 in digestive tract cancers: a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data.

Authors:  Dan-Dan Xiong; Rong-Quan He; Ai-Hua Lan; Wen-Jie Chen; Yi-Huan Luo; Zhi-Hua Ye; Jie Ma; Gang Chen; Yi-Wu Dang
Journal:  Oncotarget       Date:  2018-01-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.